BP3m controlled release - AlteogenAlternative Names: Nex-BP3m
Latest Information Update: 23 Dec 2015
At a glance
- Originator Alteogen
- Developer Alteogen; BioCure
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Chronic obstructive pulmonary disease
Most Recent Events
- 23 Dec 2015 Early research in Chronic obstructive pulmonary disease in South Korea (unspecified route)